On rotary tablet presses fitted with 10-station D-tooling and a force feeder operating at 40 rpm, fursultiamine hydrochloride blends containing 20.0% w/w active pharmaceutical ingredient exhibit electrostatic segregation when the granulation area relative humidity exceeds 45% RH; the crystalline fraction preferentially adheres to stainless steel hopper walls and to the feeder paddle surfaces, causing label-claim drift of ±6.5% across a 200,000-tablet compression run. To maintain compliance with USP <905> Uniformity of Dosage Units, the formulation is constrained to a direct compression matrix of spray-dried mannitol Pearlitol 200SD, microcrystalline cellulose PH102, croscarmellose sodium at 3.0% w/w, and magnesium stearate lubricant at 0.5% w/w. The API addition ratio is 50 mg per 250 mg core, equivalent to 20% w/w; a 100 mg unit strength uses a 500 mg core with identical excipient proportions to avoid revalidation. Lactose is excluded from the direct compression system because the aromatic amine in fursultiamine hydrochloride undergoes Maillard adduct formation with reducing sugars.

Blending is executed in a 1500 L bin blender at 10 rpm for 10 min after pre-sieving the API through a 500 μm stainless steel screen. Compression is performed at 15–20 kN pre-compression and 40–60 kN main compression using a 19 mm flat-faced bevel-edge punch set. Tablet hardness is maintained at 60–100 N, with friability below 0.8% when tested according to USP <1216>; disintegration time in 0.1 N HCl at 37°C remains below 15 min, while dissolution at 75 rpm in 900 mL of 0.1 N HCl meets USP <711> criteria of Q=80% at 30 min. The API lot must conform to the Japanese Pharmacopoeia JP 18 monograph for Fursultiamine Hydrochloride, with related substances NMT 0.5% total, residual solvents per ICH Q3C, and elemental impurities per ICH Q3D. Finished dosage forms are film-coated with Opadry II complete film coating system at 2.5% w/w weight gain in a perforated pan coater at inlet air temperature 60–65°C, then packed into PVC/PVDC blisters or 60 mL HDPE bottles containing 1 g silica gel desiccant. Terminal product types include 25 mg, 50 mg, and 100 mg film-coated tablets; scored versions for dose splitting are manufactured with a 1.0 mm bisect line and hardness adjusted to 80–100 N to prevent chipping.

What Limits Powder Flow and Weight Variability When Encapsulating Fursultiamine Hydrochloride on Dosator Machines?

On a Zanasi 40E dosator capsule filler, the low bulk density of unmilled fursultiamine hydrochloride (0.35–0.45 g/cm³) and high electrostatic charge produce weight variation exceeding ±5% RSD when line speed exceeds 25,000 capsules/h; the failure mode is intermittent powder bridging at the dosator tip and ejection of partially filled size 1 capsules at the closing station. Compliance is anchored to USP <905> Uniformity of Dosage Units, USP <711> Dissolution, USP <1174> Powder Flow, JP 18 Fursultiamine Hydrochloride monograph, and ICH Q3D elemental impurities. The API addition ratio is 50 mg per size 1 capsule with a 230 mg excipient fill, equal to 17.9% w/w; a 100 mg strength uses a size 0 capsule with 350 mg fill, equal to 28.6% w/w. The downstream process is dry granulation by roller compaction: fursultiamine hydrochloride is dry-blended with mannitol 200SD, microcrystalline cellulose PH102, and 2.0% w/w crospovidone in a 200 L drum blender for 15 min, then compacted with a 100 mm diameter ribbed roll at 20–30 kN/cm linear force and a gap of 1.5 mm; the resulting ribbons are milled through a 1.0 mm screen to produce granules with bulk density 0.55–0.60 g/cm³. After lubrication with 0.5% w/w sodium stearyl fumarate, encapsulation proceeds at 30,000–40,000 capsules/h without exceeding ±2.5% fill weight RSD. The process avoids wet granulation because fursultiamine hydrochloride is deliquescent at RH above 75% and the disulfide bridge undergoes hydrolysis in presence of free water at elevated temperature. Finished product types include hard gelatin capsules and HPMC vegetarian capsules in PVC/PVDC blister or HDPE bottles with desiccant; each batch is tested for disintegration time below 15 min in 0.1 N HCl using USP <701> apparatus.

Wet Granulation and Fluid-Bed Drying Boundaries for Single-Dose Granule Sachets

In a Glatt GPCG 5 fluid bed granulator with a 10 L product bowl, fursultiamine hydrochloride is granulated with a 5.0% w/w aqueous solution of povidone K30, sprayed at a rate of 15 g/min and atomising air pressure of 2.0 bar; the granulation endpoint is reached when particle size distribution reaches 80% by mass between 125 μm and 710 μm and loss on drying is 8–10%. If the product temperature exceeds 55°C during drying, the thiamine disulfide structure shows increased oxidative degradation products, detected as a rise in total related substances from 0.3% to 1.2% within 2 h; therefore, inlet air temperature is capped at 60°C and exhaust air at 40°C. Compliance for this dosage form includes JP 18 Granules general monograph, USP <905> for dose uniformity of single-unit sachets, USP <61> and <62> for aerobic microbial and yeast/mold limits, and ICH Q3D. The API addition ratio is 50 mg per 2.0 g sachet, corresponding to 2.5% w/w; 100 mg sachets use 4.0 g total fill and a 2.5% w/w API loading to preserve blend uniformity. The downstream process continues with sieving through 18 mesh (1.0 mm) and 60 mesh (250 μm) screens, followed by lubrication with 0.25% w/w magnesium stearate and filling into 40 mm × 60 mm four-side-sealed foil-laminate sachets at 22°C and 20% RH. Terminal finished product types include unit-dose granule sachets for oral solution, multidose 100 mL HDPE bottles containing 20 doses, and dry syrup formulations reconstituted with 70 mL potable water to form a 10 mg/mL oral suspension. Lactose is excluded from the sachet formula due to Maillard reaction risk with the aromatic amine; sorbitol is also avoided because residual moisture above 2.0% leads to granule agglomeration during storage.

Aseptic processing of aqueous fursultiamine hydrochloride solution at 10 mg/mL requires closed-system nitrogen blanketing because dissolved oxygen above 0.2 mg/L accelerates oxidative degradation that darkens the solution from pale yellow to amber within 24 h at 25°C; the degradation pathway involves oxidation of the disulfide bridge to sulfoxide and sulfonic acid species, which are detected by HPLC as related substances rising to 0.8–1.0% if headspace oxygen exceeds 2.0% v/v. The formula addition ratio is 10 mg API per 1 mL solution, with sodium chloride 9 mg/mL for isotonicity, sodium metabisulfite 0.1% w/v as antioxidant, and water for injection to 1 mL; the pH is adjusted to 3.5–4.5 with 1 N HCl or 1 N NaOH. The downstream process is performed in a Grade A/RABS filling line with a 0.22 μm polyethersulfone filter; the bulk solution is sparged with nitrogen for 30 min to reduce dissolved oxygen below 0.1 mg/L, then sterilised by membrane filtration and filled into 2 mL amber glass ampoules or 5 mL Type I borosilicate vials, followed by terminal sterilisation at 121°C for 15 min only if stability data confirm ≤0.1% individual impurity increase; otherwise, aseptic filtration without terminal heat is used. Compliance is demonstrated against USP <1> Injections, USP <71> Sterility, USP <85> Bacterial Endotoxins with limit NMT 0.5 EU/mg, USP <788> Particulate Matter in Injections, USP <790> Visible Particulates, Ph. Eur. 5.1.1 Depyrogenation, EU GMP Annex 1, and JP 18 Fursultiamine Injection monograph. Terminal finished product types include 20 mg/2 mL and 50 mg/5 mL injectable solutions, 10 mg/mL IM/IV ampoules, and 10 mL multidose vials with antimicrobial preservative 0.5% w/v phenol where registered. Incompatibility is confirmed with copper and iron ions, which catalyse disulfide bond cleavage; therefore, the formulation excludes phosphate buffers above 10 mM and any contact with stainless steel fittings lacking electropolish.

When Lyophilized Cake Residual Moisture Exceeds 1.2%, Reconstitution Time and Monomer Purity Shift Outside Specification

Freeze-dried fursultiamine hydrochloride for injection is formulated at 20 mg per 10 mL Type I glass vial with mannitol 100 mg as bulking agent and glycine 20 mg as stabiliser, giving an API addition ratio of 16.7% w/w dry solids. The solution is filled at 20°C under nitrogen, then loaded into an SP VirTis Genesis pilot lyophilizer with 0.5 m² shelf area. The freezing step decreases shelf temperature to -45°C at 0.5°C/min and holds for 3 h; primary drying is conducted at shelf -10°C and chamber pressure 150 mTorr for 24 h, followed by secondary drying at 25°C for 6 h to achieve residual moisture below 1.0% by Karl Fischer titration according to USP <921> Method Ia. When residual moisture exceeds 1.2%, reconstitution time with 10 mL water for injection rises from 30 s to over 3 min and cake collapse is observed as shrinkage at the vial wall, while related substances increase by 0.2–0.4% during 6 months at 40°C. Compliance for this dosage form covers USP <71> Sterility, USP <85> Bacterial Endotoxins, USP <1> Injections, Ph. Eur. 2.2.32 Loss on Drying, Ph. Eur. 5.1.1 Depyrogenation, and EU GMP Annex 1. Downstream processing includes aseptic filtration through a 0.22 μm PVDF membrane, filling into depyrogenated vials under Grade A conditions, partial stoppering with 20 mm bromobutyl rubber stoppers, and capping after drying. Terminal finished product types include 20 mg single-dose lyophilized vials for IM/IV administration after reconstitution, 50 mg high-strength vials for hospital use, and 5 mg paediatric vials with 1 mL water for injection diluent supplied in a separate ampoule. Published data for fursultiamine-specific lyophilization collapse temperatures is limited; the process parameters above derive from class behaviour of thiamine disulfide salts and must be verified by freeze-drying microscopy for each API lot.

Oral Disintegrating Tablet Tooling, Friability Limits, and Barrier Packaging for 50 mg Fursultiamine HCl

Oral disintegrating tablets containing 50 mg fursultiamine hydrochloride are compressed on a 12 mm convex, bevel-edge punch set to a tablet weight of 150 mg, giving an API addition ratio of 33.3% w/w. The formulation consists of coprocessed mannitol Pearlitol Flash 55.0% w/w, microcrystalline cellulose PH102 8.0% w/w, crospovidone 3.0% w/w, sucralose 0.5% w/w, peppermint flavour 0.2% w/w, and magnesium stearate 0.25% w/w. Compression force is limited to 10–15 kN to maintain disintegration time below 30 s in 5 mL water at 25°C according to USP <701>; at force above 20 kN, the tablet hardness exceeds 40 N but in vitro disintegration increases to 120 s, failing the acceptance criterion. Compliance includes USP <905>, USP <1216> with friability limit ≤1.0%, USP <921> moisture content ≤2.0%, JP 18 Fursultiamine Hydrochloride monograph, and ICH Q3D. Downstream production is direct compression without granulation; API is pre-sieved through 300 μm, preblended with crospovidone for 5 min in a 50 L V-blender, then blended with remaining excipients for 10 min at 15 rpm. Lubrication is performed for 3 min to avoid overlubrication, which would increase disintegration time beyond 30 s due to hydrophobic coating of crospovidone. Terminal finished product types include 50 mg and 100 mg orally disintegrating tablets in aluminium/aluminium peel-off blisters with 1 g molecular sieve desiccant; the packaging restricts moisture ingress to maintain tablet friability below 1.0% and disintegration below 30 s after 24 months at 30°C/65% RH. The formulation excludes gelatin and other animal-derived excipients to accommodate preference for vegetarian dosage form.